关于董事、监事、高级管理人员等自愿增持 本公司股份计划实施完毕的公告 本公司董事会、全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：601916 证券简称：浙商银行 公告编号：2025-056 浙商银行股份有限公司 重要内容提示： 已披露增持计划情况 二、增持计划的主要内容 增持主体自 2025 年 4 月 9 日起 6 个月内（如期间存在 N 个交易日限制董事、 监事、高级管理人员买卖股票，则上述期限顺延 N 个交易日）拟通过上海证券交 易所交易系统集中竞价交易方式自愿增持本公司 A 股股份，本次增持计划不设价 格区间，合计增持金额不少于 2,000 万元人民币。具体内容详见本公司于 2025 年 4 月 9 日披露的《浙商银行股份有限公司关于董事、监事、高级管理人员等自 愿增持本公司股份计划的公告》（公告编号：2025-018）。 三、增持计划的实施结果 浙商银行股份有限公司（以下简称"本公司"）于 2025 年 4 月 9 日披露了《浙 商银行股份有限公司关于董事、监事、高级管理人员等自愿增持本公司股份计划 的公告》（公告编 ...

MACD金叉信号形成，这些股涨势不错！ 格隆汇12月16日丨浙商银行(601916.SH)公布，截至2025年12月16日，本公司部分董事、监事、高级管 理人员及总行部门、分行、子公司主要负责人通过上海证券交易所系统以集中竞价交易方式累计增持本 公司A股股份671.22万股，累计增持金额2104.31万元，占本次增持股份计划金额下限的105.22%，本次 增持计划实施完毕。 ...

MACD金叉信号形成，这些股涨势不错！ 格隆汇12月16日丨浙商银行(601916.SH)公布，截至2025年12月16日，相关增持主体通过上海证券交易 所系统以集中竞价交易方式累计增持本公司A股股份671.22万股，累计增持金额2104.31万元，占本次增 持股份计划金额下限的105.22%，本次增持计划实施完毕。 ...

Group 1 - Lingban Technology has opened its first flagship store in Wuhan, showcasing its self-developed AR glasses across various scenarios including government, industrial, and daily life applications [1][3] - The company, which established its presence in Wuhan in September 2024, has made significant strides in commercialization within just one year, aided by tailored financial support from Zhejiang Commercial Bank's Wuhan branch [1][4] Group 2 - Zhejiang Commercial Bank's Wuhan branch has adapted its evaluation approach for tech companies, shifting focus from tangible assets to assessing "talent accounts" and "technology flows," recognizing the importance of intellectual capital and data resources [4][8] - In April 2025, the bank introduced a "shared risk mechanism" and provided Lingban Technology with a 10 million yuan "Innovation Shared Loan" to facilitate market entry and transition from R&D to application [5][8] Group 3 - The bank's "Shan Ke Accompanying Plan" aims to support tech companies throughout their lifecycle, offering over 30 specialized financial products tailored to various stages from startup to maturity [5][8] - Zhejiang Commercial Bank has served 804 tech enterprises to date, providing 4.295 billion yuan in new financing support this year alone, reflecting its commitment to fostering innovation in Wuhan [11]

Market Overview - The A-share market experienced a collective pullback, with the ChiNext Index leading the decline at 1.77%. The total trading volume in the Shanghai and Shenzhen markets was 1.77 trillion yuan, a decrease of 318.8 billion yuan from the previous trading day [1][22]. - Despite the overall market decline, sectors such as commercial aerospace and satellite internet remained strong, with the Aerospace Electronics stock hitting a historical high and the National Defense and Military Industry ETF (512810) rising by 1.54%, reaching a two-month high [1][6]. Sector Performance - The National Defense and Military Industry ETF (512810) saw significant inflows, with a net inflow of 6.181 billion yuan, the highest among 31 first-tier industries, and a total of 19.778 billion yuan over the past five days [28][29]. - The Food ETF (515710) also showed resilience, with a peak increase of 1.36% during the day and a total inflow of 65.61 million yuan over the past five days, driven by a recovery in liquor prices, particularly for Moutai [1][33]. - The brokerage sector is expected to distribute nearly 9 billion yuan in dividends, with 80% of listed brokerages planning at least two dividend distributions this year [1][22]. Investment Strategies - Analysts suggest focusing on three key areas for investment: growth sectors benefiting from industrial policy support (e.g., domestic production, robotics, aerospace), cyclical sectors benefiting from "anti-involution" policies (e.g., chemicals, energy metals), and consumer sectors that may see a boost from deepened consumption policies [25]. - The National Defense and Military Industry sector is rated as "overweight" by institutions, with a focus on core assets in commercial aerospace, low-altitude economy, and military AI [30][32]. Future Outlook - The market sentiment is supported by recent meetings of the Federal Reserve and domestic policy-making bodies, which align with market expectations. Historical data suggests that the A-share market tends to perform well in the first year of the 13th and 14th Five-Year Plans, indicating potential for a strong cross-year market [24][25]. - The banking sector is also positioned for recovery, with all 42 listed banks currently trading below their net asset value, suggesting a potential for valuation recovery [19].

Core Viewpoint - The article highlights the breakthrough in gene therapy for thalassemia by Kanglin Biotech, which has made significant advancements in making treatment more accessible and affordable, aided by innovative financial products like "talent loans" and "technology achievement transformation loans" [1][2][3][10]. Group 1: Gene Therapy Breakthrough - Kanglin Biotech has developed the KL003 cell injection, achieving significant progress in treating thalassemia, with over 30 patients receiving stem cell infusions in just three months [2]. - The cost of KL003 is significantly lower than the previously available gene therapy in the U.S., which was priced at $2.8 million, making it more accessible to patients [6]. Group 2: Financial Support and Innovation - The "talent loan" program, initiated by Zheshang Bank, has provided substantial financial support to Kanglin Biotech, allowing for a credit loan of up to 15 million yuan, facilitating the company's research and development [3][4]. - By the end of October, over 80.9 billion yuan in "talent loans" had been issued across Zhejiang province, demonstrating the effectiveness of this financial innovation in supporting startups [3]. Group 3: Technology Transfer and Collaboration - The establishment of the National University Biomedicine Regional Technology Transfer Center in Jiangsu has facilitated the transformation of research outcomes into practical applications, with 62 projects successfully transitioned from 1,572 selected medical achievements [7][9]. - The center has created a comprehensive financial support system, accumulating 2.25 billion yuan in project financing, which aids in overcoming the challenges of technology transfer in the biomedicine sector [9]. Group 4: Future Prospects - The introduction of "technology achievement transformation loans" aims to lower barriers for startups in the biomedicine field, providing 4.5 billion yuan in credit to 42 projects, thus enhancing the efficiency of funding for research and development [10]. - The combined efforts in Jiangsu and Zhejiang provinces are expected to enable more patients to access affordable medications and support the biomedicine industry in transitioning from a follower to a leader in innovation [10].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 CHINA ZHESHANG BANK CO., LTD. 浙商銀行股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2016） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10(B)條作出。 证券代码：601916 证券简称：浙商银行 公告编号：2025-055 浙商银行股份有限公司 第七届监事会第十五次会议决议公告 如下公告已於上海證券交易所網站刊登，僅供參閱。 特此公告。 承董事會命 浙商銀行股份有限公司 陳海強 執行董事、行長 中國，杭州 2025年12月15日 截至本公告日期，本行的執行董事為陳海強先生及馬紅女士；非執行董事為侯興 釧先生、任志祥先生、胡天高先生及應宇翔先生；獨立非執行董事為汪煒先生、 許永斌先生、傅廷美先生、施浩先生及樓偉中先生。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准 ...

证券代码：601916 证券简称：浙商银行 公告编号：2025-055 浙商银行股份有限公司 第七届监事会第十五次会议决议公告 1 浙商银行股份有限公司第七届监事会第十五次会议于2025年12月1日发出会 议通知，以书面传签方式召开，表决截止日为2025年12月15日。本次会议应出 席监事10名，实际参与书面传签表决的监事共10名。本次会议的召开符合法律、 法规、部门规章、其他规范性文件和《浙商银行股份有限公司章程》的有关规 定。 会议审议通过了以下议案： 一、通过《2025年度本行监事会对董监高履职评价的工作方案》。 表决结果：10票赞成，0票反对，0票弃权。 特此公告。 浙商银行股份有限公司监事会 2025 年 12 月 15 日 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

Core Insights - The article highlights the innovative financing solutions provided by Zheshang Bank's Jining branch to support the garlic industry in Jinxing County, addressing the financing challenges faced by small and medium-sized garlic merchants [1][4][6]. Industry Overview - Jinxing County, known as the "Garlic Capital," accounts for over 70% of China's garlic trading volume and has an annual industry output value of 68.8 billion yuan, with a public brand value exceeding 21.8 billion yuan [2]. - The garlic industry has developed a complete supply chain from planting to processing, but financing bottlenecks hinder the full release of market potential [2][4]. Financing Challenges - Small and medium garlic merchants face three main issues: insufficient collateral, lack of formal financial management, and low financing efficiency due to cumbersome traditional loan approval processes [2][3]. - Many merchants struggle with capital shortages during peak purchasing seasons, often missing favorable market conditions due to slow loan approvals [3][6]. Innovative Solutions - Zheshang Bank has introduced a "garlic warehouse receipt pledge financing" system, allowing merchants to use stored garlic as collateral for loans, thus transforming static inventory into liquid financial capital [4][5]. - The bank collaborates with local government, leading agricultural enterprises, and third-party storage institutions to create a comprehensive financial service system that includes real-time monitoring and risk management [5][6]. Impact and Results - The garlic warehouse receipt pledge financing has already benefited over 50 core storage and processing enterprises in Jinxing County, with total loans exceeding 360 million yuan, effectively activating hundreds of thousands of tons of garlic inventory [6]. - The bank has also launched a digital financial product, "Shuyidai," to provide flexible financing support to small merchants, further reducing their financing costs and time [6][7]. Future Prospects - Zheshang Bank aims to replicate the successful "garlic model" in other local industries, enhancing financial product innovation and collaboration with government and industry associations to accelerate financial empowerment of local economies [7].

| 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 605388 | 均瑶健 康 | 10.04 | 3.39 | 7.27 | 7.89 | 8.59 | | 600271 | 航天信 息 | 10.00 | 4.46 | 8.97 | 9.68 | 7.93 | | 002187 | 广百股 份 | 9.96 | 7.00 | 6.98 | 7.51 | 7.58 | | 920786 | 骑士乳 业 | 10.97 | 18.10 | 9.94 | 10.52 | 5.88 | | 002053 | 云南能 投 | 10.00 | 2.17 | 11.53 | 12.21 | 5.87 | | 003019 | 宸展光 电 | 5.92 | 4.61 | 31.59 | 33.29 | 5.38 | | 002382 | 蓝帆医 疗 | 10.00 | 2.40 | 5.50 | 5.72 | ...